Treatment progress of non-small cell lung cancer with RET gene fusion

VernacularTitle:RET基因融合非小细胞肺癌的治疗进展
Author: Xiaoxue LI ¹ ; Kejian SHI ; Shuyang YAO ; Jingying NONG ; Xiuyi ZHI
Author Information

1. 首都医科大学宣武医院胸外科，北京　100053
Keywords: Carcinoma, non-small-cell lung; Gene, RET; Fusion; Targeted therapy
From: Cancer Research and Clinic 2022;34(7):547-550
CountryChina
Language:Chinese
Abstract: Non-small cell lung cancer (NSCLC) is a malignant tumor with rapid progress and high malignancy, accounting for 85% of all lung cancers. Treatment has shifted from traditional surgery, radiotherapy and chemotherapy to targeted therapy. Targeted therapy can prolong the survival of patients with positive driver gene fusion. With the continuous progress of biological research, targets related to NSCLC have gradually been discovered. Among the many driving genes of NSCLC, RET fusion is an important emerging target discovered in recent years. It has been confirmed to have a high incidence in non-smoking, young and low-differentiated NSCLC patients. This article reviews RET gene fusion in NSCLC, the relationship between the two and the treatment progress.